Characterization of splice variants of human caspase-activated DNase with CIDE-N structure and function  by Bayascas, José R. et al.
FEBS Letters 566 (2004) 234–240 FEBS 28415Characterization of splice variants of human caspase-activated
DNase with CIDE-N structure and functionJose R. Bayascas1, Vıctor J. Yuste1, Carme Sole, Isabel Sanchez-Lopez, Miquel F. Segura,
Remei Perera, Joan X. Comella*
Grup de Senyalitzacio Cel.lular i Apoptosi, Departament de Ciencies Mediques Basiques, Universitat de Lleida, 25008 Lleida, Spain
Received 30 March 2004; accepted 21 April 2004
Available online 3 May 2004
Edited by Vladimir SkulachevAbstract Internucleosomal DNA fragmentation is an apoptotic
event that depends on the activity of diﬀerent nucleases. Among
them, the DNA fragmentation factor B, better known as
caspase-activated DNase (CAD), is mainly responsible for this
DNA fragmentation in dying cells. CAD is an endonuclease that
is chaperoned and inhibited by inhibitor of CAD (ICAD).
Activation of CAD needs the cleavage of ICAD by activated
caspase-3. During the characterization of the staurosporine-
induced apoptotic process in human neuroblastoma cell lines, we
have found three novel splice variants of CAD. In all three
messengers, the open reading frame is truncated after the second
exon of the CAD gene. This truncated open reading frame
codiﬁes the CAD protein amino terminal part corresponding to
the cell death-inducing DFF45-like eﬀector-N (CIDE-N) do-
main. We have detected these splicing variants in human tissues
and in peripheral white blood cells from 10 unrelated individuals,
and their products have been showed to be expressed in certain
mouse tissues. We demonstrate that these truncated forms of
CAD are soluble proteins that interact with ICAD. We also
provided evidences that these CIDE-N forms of CAD promote
apoptosis in a caspase-dependent manner.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis is a death process that plays an essential role in
animal development and tissue homeostasis [1]. Chromatin
condensation and internucleosomal DNA fragmentation are
one of the main characteristic nuclear features and some of the
best-recognized events in apoptotic cells [2]. These nuclear
changes are mainly triggered by the DNA fragmentation fac-
tor (DFF) [3–8]. DFF complex is composed of two subunits,* Corresponding author. Fax: +34-973-702-426/438.
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hyde-3-phosphate dehydrogenase
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.04.050an endonuclease of 40 kDa named DFFB, also known as
CPAN [5], caspase-activated DNase (CAD) [6] or DFF40 [7],
and its inhibitor of 45 kDa named DFFA, also known as
DFF45 [3] or inhibitor of CAD (ICAD) [8]. Here, we will refer
to them as CAD and ICAD, respectively. ICAD is complexed
with CAD in proliferating cells. When apoptosis is activated,
executor caspases cleave ICAD at two Asp residues (D117 and
D224) [6,8]. Cleaved ICAD is no longer able to inhibit CAD
and nuclease release results in the cleavage of DNA at inter-
nucleosomal sites. There are two forms of ICAD that are
generated by alternative splicing, ICAD-L and ICAD-S, for
long and short forms, respectively [8]. Although both forms of
ICAD can inhibit CAD nuclease activity, only ICAD-L to-
gether with Hsp70 and Hsp40 functions as a chaperone and is
required for the production of functional CAD [9]. Moreover,
experiments conducted with CAD and ICAD-null cells dem-
onstrated that both CAD and ICAD-L mutually control their
expression at the post-transcriptional level [10]. Thus, the DFF
system ensures that a cell only undergoes DNA fragmentation
when it receives apoptotic signals [11]. As both the human
ICAD and CAD genes map to 1p36 [4,12], a region which is
frequently deleted in neuroblastomas [13,14] and other tu-
mours, a role for the DFF complex in malignal transformation
has been suggested [15,16].
Although the contribution of other DNases, such as en-
donuclease G [17], AIF-activated DNase [18], and more re-
cently Ape1 [19], to the apoptotic DNA fragmentation has
also been proposed, CAD-null cells did not show DNA
degradation upon apoptosis induction [20]. However, mice
deﬁcient in CAD showed no gross developmental abnor-
malities and were still able to undergo apoptotic chromo-
somal degradation. Disruption of both CAD and DNase II
genes has been conducted in mice [20] and Drosophila [21].
The study of the double knockouts has led the authors to
propose that the degradation of chromosomal DNA during
apoptosis is mediated in vivo by two systems. One depending
on the DFF complex and operating cell autonomously, and
the other depending on the activity of DNase II inside the
phagocytes [22].
CAD consists of two domains with diﬀerentiated functions.
Its C-terminal domain displays DNA nuclease activity,
whereas the N-terminal domain shows a regulatory role
[23,24]. N-terminal domain of CAD is similar to N-terminal
domain of ICAD and it has been demonstrated that the
binding of the two proteins is due to homophilic interactions
between the two N-terminal motifs [24–26]. The group ofblished by Elsevier B.V. All rights reserved.
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teins structurally related to DFFs that they named CIDE
(cell death-inducing DFF45-like eﬀector). CIDE family is
composed of three members, CIDE-A, CIDE-B and Fsp27
[27]. CIDE-3 has also been recently characterized as the hu-
man Fsp27 homologue [28]. Apoptosis-inducing eﬀects of
CIDE reside in its C-terminal domain. Both dimerization of
the CIDE-C domain and mitochondrial localization of the
CIDE dimers are essential for the induction of apoptosis [29].
Moreover, the diﬀerent CIDEs share an N-terminal domain,
the CIDE-N domain, homologous to the N-terminal domain
of DFFs that mediates homophilic interactions with other
CIDE-N domain-containing proteins. It has also been pro-
posed that the CIDE-N of CIDE-B is able to sequester
CIDE-N of ICAD from the DFF complex, thus releasing the
nuclease function of CAD. These results also suggest that the
diﬀerent CIDE-N domains show displaceable binding [24].
While characterizing the cell death process induced by
staurosporine (STP) in human neuroblastoma cell lines, we
discovered three novel splice variants of CAD. Here, we re-
port that these variants are produced from an aberrant
splicing in the second intron of the CAD gene, which intro-
duces a new stop codon and premature termination. These
new CAD splice variants are not exclusive of neuroblastoma
cells, since we have detected them in other human cell lines
and in a number of human tissues, as well as in peripheral
lymphocytes from 10 unrelated individuals. We have also
demonstrated the expression of the corresponding truncated
peptides in several mouse tissues. We ﬁnally provided evi-
dences that these truncated proteins are structurally and
functionally equivalent to the CIDE-N domain of the CIDE
proteins and could promote apoptosis in a caspase-dependent
manner.2. Materials and methods
2.1. Ampliﬁcation and sequencing of CAD
One microgram of total RNA was reverse transcribed with 10 pmols
of the speciﬁc downstream primer DFFBR as described below. Five
nanograms of cDNA was ampliﬁed by PCR in a Perkin–Elmer
Thermal Cycler 2400 with 200 nM each of DFFBF (50-
TGCAATGCTCCAGAAGCCCAAGAGC-30) and DFFBR (50-
TCACTGGCGTTTCCGCACAGGCTG-30) primers. PCR conditions
were 94 C/20 s, 65 C/20 s, 72 C/1 min, for 35 cycles, in 50 mM Tris–
HCl, pH 9.0, 2.5 mM MgCl2, 15 mM (NH4)2SO4, 0.1% Triton X-100,
and 1 U DyNAzime EXT DNA Polymerase (Finnzymes).
2.2. RT-PCR analysis
One microgram of RNA from either human neuroblastoma cell lines
or lymphocytes was treated with 2 U DNase RNase free (Pharmacia)
and reverse transcribed using 800 pmol of random hexamers (Roche
Diagnostics), and 200 U MMLV-RT (Promega) for 1 h at 42 C. To
study the tissue distribution of the CAD splice variants, Human
Multiple Tissue cDNA Panels I and II (Clontech, BD Biosciences)
were analyzed.
Approximately 5 ng of cDNA was PCR ampliﬁed with the Herculase
Hotstart DNA polymerase (Stratagene) as described for the CAD am-
pliﬁcation, except for the reduction of the elongation time to 30 s.
Primers used were: DFFBF (described above), CADIntR (50-
CCTGATGTCGCTCACATCTGCCAC-30), which detect speciﬁcally
the 7 and 50 bp insertions, and CADIntF (50-CTGGCAGGGCTGT
GAGTGGCA-30), CADR3 (50-TCTCAGATAGCCAGACTTGCT-
CTG-30), which amplify the 22 bp insertion, where CADIntF and
CADIntR have been designed from the exon–intron boundary sequence
[30] (see Fig. 1A). As a control, the RNA of the housekeeping L27
ribosomal protein was also ampliﬁed with 20 nM each primer in amultiplex reaction [31]. For the human cDNA panels, a set of com-
mercial primers was used to amplify the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) messenger.
2.3. Detection of CAD isoforms in mouse tissues
Mouse adult tissues were dissected and extracted in a 10-fold mass
excess of ice-cold PD lysis buﬀer (40 mM Tris, pH 8.0, 500 mM sodium
chloride, 6 mM EDTA, 6 mM EGTA, 0.1% Nonidet NP40, 10 mM b-
glycerophosphate, 10 mM NaF, 300 lM Na3VO4, 1 mM DTT, 2 lM
PMSF, 1 mM benzamidine, 10 lg/ml aprotinin, 1 lg/ml leupeptin and
1 lg/ml pepstatin). Twenty-ﬁve micrograms of protein was resolved in
15% SDS–PAGE and probed with the mouse Nt-CAD (Prosciences??)
and the human CAD FL-338 (SantaCruz Biotechnology, sc-8342)
antibody.
2.4. Cell lines and peripheral leukocytes
Human neuroblastoma cell lines IMR-5 [32] and SH-SY5Y [33] were
kindly provided by Dr. Dionisio Martın-Zanca (Salamanca, Spain)
and were cultured in DMEM containing 10% and 15% fetal calf serum,
respectively. Human embryonic kidney 293T cells [34] were cultured in
MEM containing 10% horse serum. Unless otherwise stated, all media
and reagents were purchased from Sigma (St. Louis, MO). Apoptosis
induction using STP was performed as described previously [35,36].
Human peripheral blood leukocyte samples from 10 healthy individ-
uals were puriﬁed with an HistoPaque gradient (Sigma) following the
manufacturer’s instructions.
2.5. Expression and analysis of solubility of CAD fragments
A total of 1 106 human 293T cells were transiently transfected with
5 lg of either the wild type or the truncated forms of CAD plasmids
using LipofectamineTM2000 (GibcoTM Invitrogen Corp). After 24 h,
cells were harvested and half of them were lysed in whole cell lysis
buﬀer (50 mM Tris–Cl–2% SDS). The other half of harvested cells were
lysed in soluble fraction buﬀer (50 mM HEPES, pH 6.8, 10 mM po-
tassium chloride, 10% sucrose, 5 mM EGTA, 2 mM magnesium
chloride and 1 mM dithiothreitol). These second fractions were then
centrifuged at 13 000 g for 10 min at 4 C and supernatant (soluble
fraction) and pellet (insoluble fraction) were recovered separately.
Soluble fraction was directly processed, whereas insoluble fraction was
resuspended in whole cell lysis buﬀer and further processed. Approx-
imately 50 lg of protein from the diﬀerent conditions was resolved in
15% SDS–PAGE. Western blotting using the anti-CAD (FL-338) an-
tibody (Santa Cruz Biotechnology, sc-8342) was performed as de-
scribed above.
A total of 1 106 human 293T cells were transiently transfected with
5 lg of the haemaglutinin (HA)-tagged constructs of the diﬀerent
forms of CAD either alone or in combination with FLAG-ICAD using
LipofectamineTM2000 (GibcoTM Invitrogen Corp). As a control of the
Z-VAD treatment, anti-apoptotic HA-Bcl-XL and pro-apoptotic HA-
Bax plasmids were also included. Transfected cultures were then
treated with 50 lM of Z-VAD-fmk or left untreated. After 24 h, cells
were lysed in whole cell lysis buﬀer (50 mM Tris–HCl–2% SDS) and
the level of expression of the diﬀerent proteins analyzed by Western
blot with the a-HA High Aﬃnity antibody (Roche Diagnostics, clone
3F10). Membranes were stripped and re-blotted with the a-green
ﬂuorescent protein (Clontech BD Biosciences) and the a-panERK
(Transduction Laboratories BD Biosciences) antibodies to control the
transfection eﬃciency and the sample loading, respectively.
2.6. Immunoprecipitation assay
A total of 3 106 human 293T cells were transiently co-trans-
fected with 25 lg of the diﬀerent forms of CAD tagged with HA at
their N-terminal region plus 15 lg of N-terminally FLAG-tagged
full-length ICAD using the calcium phosphate method. After 24 h,
cells were harvested in lysis buﬀer PD, lysates were clariﬁed by
centrifuging at 12 000 g and 25 lg of protein of the supernatant
was resolved in 15% SDS–PAGE. Western blotting using the a-HA
High Aﬃnity antibody (clone 3F10) (Roche Diagnostics) and the
anti-FLAG M2 monoclonal antibody (Sigma) was performed. Al-
ternatively, 1 mg of cleared supernatants was subjected to immu-
noprecipitation with 2 lg of the anti-FLAG antibody overnight at
4 C. Antibodies were recovered with protein-G and samples were
resolved in 15% SDS–PAGE. Western blotting was performed using
the anti-HA antibody.
Fig. 1. Alternative spliced forms of the CAD gene are detected in neuroblastoma cell lines. (A) Sequence analysis of IMR-5 CAD RNAs population.
Alignment of the alternative RNAs with the exon 2/intron 2 and the intron 2/exon 3 border sequences revealed an incorrect recognition of the donor
site for the 22 bp insertion (CADþ22), and a miss-recognition of the acceptor site for the 7 bp (CADþ7) and 50 bp (CADþ50) insertions. All the
alternative splicing sites are in good agreement with the donor and acceptor consensus sites. The positions that are more conserved in the alternative
transcripts compared with the CAD messenger are underlined. (B) Amino-acid alignment of the predicted truncated products with the full length
CAD protein. Conceptual translation of these splicing variants give rise to truncated peptides of 110, 115 and 80 amino acids for the mRNAs with 7,
22 and 50 bp insertions, respectively, which contain the CIDE-N domain. Positions identical to the full length CAD protein [4] are shaded. Asterisks
indicate stop codon. CADþ7, CADþ22 and CADþ50 sequences have been deposited in the GenBank database under accession numbers AF409060,
AF409061 and AF409062, respectively.
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A total of 5 105 human 293T cells were co-transfected in triplicate
with 2 lg of the adequate expression plasmids using Lipofecta-
mineTM2000 (GibcoTM Invitrogen Corp). The diﬀerent forms of CAD
were tagged with HA at their N-terminal region, whereas the ICAD
was N-terminally FLAG-tagged. One microgram of enhanced green
ﬂuorescent protein (eGFP) was included systematically in the co-
transfection to recognize transfected cells during counting. The total
amount of plasmid transfected was adjusted with empty-pcDNA3 to
be always the same in individual experiments. Twelve hours after
transfection, cells were treated with 1 lM STP for 20 h or left un-
treated, and nuclei were stained for 30 min with 0.5 lg/ml of Hoechst
33258. The number of apoptotic versus normal nuclei in eGFP ex-
pressing cells was scored using an inverted Olympus microscope
equipped with epiﬂuorescence optics under UV illumination. Experi-
ments were repeated four times and not less than 300 cells were
counted per condition. Statistical signiﬁcance was determined by
Student’s t-test. To control the level of expression of the diﬀerent
constructs, the same dishes used for the scoring were extracted in
RIPA buﬀer and 50 lg of protein from diﬀerent conditions was re-
solved in 15% SDS–PAGE. Western blotting using the anti-FLAGM2
antibody (Sigma), the Anti-HA antibody (Roche Diagnostics) and the
anti-eGFP antibody (Clontech) was performed as described.3. Results
3.1. Caspase-activated DNase gene shows alterations in the
splicing of the second intron
STP is a powerful and non-speciﬁc inhibitor of protein ki-
nases that has been established so far as an eﬀective inductor of
apoptotic cell death [35–39]. During the characterization of the
STP-induced apoptotic process in neuroblastoma cells, we
observed that IMR-5 cells did not show internucleosomal
DNA fragmentation irrespective of the times and concentra-
tions of STP used [35]. IMR-5 cells expressed normal levels ofCAD but upon STP-induced cell death, CAD rapidly disap-
peared from cytosolic fractions. This fact explains the absence
of oligonucleosomal degradation of DNA, since forced over-
expression of CAD restored the laddering during apoptosis
[36].
We further characterized the CAD gene by sequencing of the
messenger. RT-PCR analysis was used to amplify the region
corresponding to the open reading frame of the human CAD
gene from human IMR-5 cells. Sequencing of several inde-
pendent clones showed a major product with a sequence
identical to that originally described by Mukae et al. [4]. Four
out of 29 clones analyzed exhibited an insertion at the position
corresponding to the exon 2–exon 3 junction (Fig. 1A). One of
these clones holds a 7 bp insertion (CADþ7), another a 22 bp
one (CADþ22), and the last two clones showed an insertion of
50 bp (CADþ50). Sequence comparison of these extra frag-
ments with the human genome sequence demonstrates that
they were generated by miss-splicing of the CAD gene second
intron, where the 7 and 50 bp insertions were produced by
using novel splice acceptors, while the 22 bp insertion was
produced by the use of a new donor site. These alternative-
splicing sites showed an even better agreement with the con-
sensus when compared with the canonical intron 2 splice sites
(Fig. 1A). All these extra sequences resulted in a frameshift
that generates a novel stop codon and premature termination
(Fig. 1B).
Conceptual translation of the alternative sequences de-
scribed above gives rise to truncated products that ﬁnish just at
the exon–intron junction (CADþ50, 80 amino acids in length)
or a few amino acids later (110 and 115 amino acids in length
for the CADþ7 and CADþ22 forms, respectively). These trun-
cated peptides share a common feature; they correspond to the
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the protein–protein interaction with ICAD [23]. Moreover, it
has been reported than the interaction between the CIDE-N
domain of CAD and ICAD is increased when a part of the
endonuclease domain is also implicated in this interaction [26].
The truncated products of 110 and 115 amino acids precisely
fulﬁl that requirement (Fig. 1B).
3.2. Splicing variants of the CAD gene are detected in
peripheral lymphocytes from normal individuals and are
widely expressed in human and mouse tissues
We designed a RT-PCR-based analysis to explore for the
presence of this kind of alternative RNAs in other cell types.
We used primers spanning the exon–intron junction (see
Fig. 1A) to avoid the ampliﬁcation of the more abundant, full-
length transcript and to detect the alternative ones. Fig. 2A
shows the detection of these new messengers in IMR5 and SH-
SY5Y neuroblastoma cells. Other cell lines such as HEK 293T,
HeLa and Jurkat also express the diﬀerent transcripts (data
not shown). Moreover, in RNA samples from lymphocytes of
10 unrelated individuals, the three products were also ampli-
ﬁed. In Fig. 2A, bands of 269 and 321 bp in upper panel
correspond to the 7 and 50 bp insertion forms, respectively,Fig. 2. Detection of the human CAD alternative transcripts in human
cell lines and tissues. (A) RT-PCR analysis of lymphocytes of ten
unrelated individuals (1–10), IMR-5 (I) and SH-SY5Y (S) neuroblas-
toma cell lines. (B) RT-PCR detection of the alternative messengers of
CAD in a panel of human tissues (Clontech). Upper panels in A and B,
detection of the 7 bp (i7) and 50 bp (i50) insertions. Lower panel in A
and middle panel in B, ampliﬁcation of the 22 bp insertion (i22). To
control the amount of RNA in each sample, co-ampliﬁcation of the
L27 ribosomal protein (L27) and ampliﬁcation of the GADPH mes-
sengers were performed in A and B, respectively. Controls without
reverse transcriptase were performed to discard genomic ampliﬁcation
(R). m, 50 bp DNA ladder marker (Pharmacia). (C) Detection of the
CAD truncated peptides in mouse tissues. Adult mouse tissues were
analyzed for the presence of the diﬀerent CAD isoforms by western
blot with the CAD FL-338 antibody. Full length CAD is detected in
the upper pannel as a single 40-kDa band in all tissues. A band of 13-
kDa corresponding to the CADþ7 and CADþ22 products and a band
of 9-kDa corresponding to the CADþ50 product, were detected in the
lower panel after a longer exposure time.and the single band of 263 bp in the lower panel corresponds
to the 22 bp one. Bands were veriﬁed by sequencing. Co-am-
pliﬁcation of the ribosomal gene L27 was carried out as a
control for cDNA input in the ampliﬁcation reaction.
We next used the same PCR strategy to analyze the ex-
pression proﬁle of the CAD splicing variants on a commercial
panel of human cDNAs. All three products were detected in a
number of tissues in a more diﬀerential rather than ubiquitous
pattern. Thus, some splice variants seem to be abundant in
spleen, ovary, heart, brain, lung, kidney and pancreas, whereas
all of them were barely detected in skeletal muscle (Fig. 2B).
The GAPDH ampliﬁed product is shown in the lower panel as
a control. Western blot analysis conﬁrmed a diﬀerential ex-
pression pattern of the corresponding CAD truncated peptides
in mouse adult tissues (Fig. 2C). Thus, two speciﬁc bands of
13- and 9-kDa were detected in liver and kidney, while single
bands of 9- and 13-kDa were detected in brain and spleen
extracts, respectively, and no bands were detected in skeletal
muscle. As the predicted mass for the CADþ7, CADþ22 and
CADþ50 products are 12.1-, 12.6- and 8.8-kDa, respectively,
the 13-kDa band might correspond to the ﬁrst two products
and the 9-kDa band to the third one. The protein expression
proﬁle match consistently with the RT-PCR data for these
tissues.
Altogether, these results demonstrate that these splicing
variants are generated in physiological conditions. Moreover,
since the cells expressing these splice variants show the typical
nuclear changes upon apoptotic induction, we were interested
in analyzing what could be the function of these CAD short
forms.
3.3. Truncated forms of CAD protein are soluble
It is well known that ICAD functions as a chaperone for
CAD and is necessary both for the expression and the main-
tenance of CAD as a soluble protein [8,9,25]. Since it has been
previously described that the insoluble character of CAD re-
sides mainly in the endonuclease domain [26], we next explored
the solubility of the truncated isoforms of CAD by Western
blot analysis of diﬀerent cellular fractions (Fig. 3A). To this
end, the diﬀerent CAD isoforms were over-expressed in HEK
293T cells. Full-length CAD was detected in the whole extract
as a single 40-kDa band and was recovered mainly from the
insoluble fraction. Moreover, a faint band in the soluble
fraction was also detected. The same proﬁle was obtained by
expressing an HA-tagged CAD construct (data not shown),
indicating that a fraction of the exogenous expressed protein
could be maintained as a soluble protein probably by inter-
acting with the endogenous ICAD. Both CADþ7 (not shown)
and CADþ22 (Fig. 3A) constructs yielded a 13-kDa protein
that was predominantly soluble, while the CADþ50 product
gave rise to a shorter 9-kDa protein that was detected mainly
in the soluble fraction (data not shown). When these products
were co-expressed together with ICAD, the cellular levels of
the truncated products clearly increased (Fig. 4A, middle pa-
nel). These results conﬁrm that ICAD is also necessary for the
proper production of the CAD short forms.
To identify the binding properties of the CAD truncated
products, FLAG-tagged ICAD was co-expressed with HA-
tagged CAD isoforms in 293T cells and immunoprecipitated
with the anti-FLAG antibody. Immunoprecipitated extracts
were analyzed by Western blot using the anti-HA antibody.
Interaction of the control wild type CAD and the CADþ22
Fig. 3. CAD isoforms are soluble and interact with ICAD. (A) HEK
293T cells were transfected with the indicated constructs and whole cell
extract (W), or soluble supernatant (S) and insoluble pellet (P) were
analyzed by western blot using a N-terminal anti-CAD polyclonal
antibody. A band of approximately 13 kDa is detected in both the
soluble and pellet fractions of cells transfected with the CADþ22
splicing construct. Full-length CAD is detected as a 40 kDa band
mainly in the insoluble fraction. (B) HEK 293T cells were co-trans-
fected with the indicated expression plasmids and the resulting cellular
lysates immunoprecipitated with the FLAG antibody. Upper panels
(INPUT), total cellular lysates blotted with the indicated antibodies to
assess equivalent expression of the diﬀerent contructs. Lower panel (IP
a-FLAG), immunoprecipitates blotted with the indicated antibodies.
CAD and CADþ22 are clearly detected with the HA antibody in the
FLAG immunoprecipitates.
Fig. 4. ICAD enhances expression of truncated forms of CAD.
Truncated forms of CAD induce a caspase-dependent cell death. (A)
293T cells expressing CADþ22 alone or in combination with ICAD
were treated with 50 lM of Z-VAD or left untreated. Both the ex-
pression of ICAD and the treatment with Z-VAD dramatically in-
creased the amount of CADþ22 protein as detected by western blot
with the a-HA antibody. As a control, the same membranes were
stripped and re-probed with a-tubulin or ERK antibodies. (B) Com-
parison of apoptosis induced with truncated forms of CAD with that
observed expressing the proapoptotic protein Bax. HEK 293T cells co-
transfected with the indicated HA-tagged proteins (Bcl-XL, Bax and
CADþ22) plus the pEGFP plasmid were treated with Z-VAD or left
untreated. Both CADþ22 and Bax protein expression are enhanced
with Z-VAD treatment as detected by Western blot with the a-HA
antibody. Western blot using the eGFP and ERK antibodies was
performed to control the transfection eﬃciency and gel loading,
respectively.
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and CADþ22 products were detected speciﬁcally in the corre-
sponding immunoprecipitates of cells transfected with FLAG-
ICAD, and were also detected speciﬁcally with the anti-HA
antibody from the cellular lysates transfected with both plas-
mids. Same results were obtained for the CADþ7 and CADþ50
forms (not shown)
3.4. Truncated forms of CAD can induce a caspase-dependent
cell death
When CAD fragments were transfected in HEK 293T cells,
the amount of N-CAD protein detected by western blot was
signiﬁcantly increased if the cultures were simultaneously
treated with the general caspase inhibitor Z-VAD (Fig. 4A and
B). This observation might be interpreted as an enrichment of
the culture on those cells expressing higher levels of the short
proteins, which otherwise will die and disappear. This ex-
pression proﬁle clearly resembles that obtained for Bax – a well
characterized pro-apoptotic molecule – and might be consid-
ered as an indirect indication of a role of the CAD truncated
forms in inducing cell death in a caspase-dependent manner.
To further understand the functionality of these alternative
products, overexpression of the diﬀerent isoforms of CAD
either alone or in combination with ICAD was carried out in
HEK 293T cells. STP-induced apoptosis, assessed by nuclearmorphology with the Hoechst 33258 staining (Fig. 5C), was
strongly inhibited by ICAD overexpression (Fig. 5A). When
whole CAD was co-expressed together with ICAD, the per-
centage of apoptotic nuclei signiﬁcantly increased, which
indicate, a recovery in the endonuclease activity levels. Pre-
vention of apoptosis by ICAD was partially reverted by
co-expression of CADþ7, CADþ22 or CADþ50, thus suggesting
that the CAD truncated forms might promote apoptosis. Al-
though the apoptotic eﬀect of short forms did not revert to the
basal situation, the number of apoptotic cells signiﬁcantly in-
creased when compared with cells transfected with ICAD
alone. Western blot analysis on the transfected cell lysates did
not demonstrate any major interference in the levels of ex-
pression between the diﬀerent constructs (Fig. 5B). Over-
expression of each diﬀerent form of truncated CAD alone did
not signiﬁcantly modify the percentage of STP-induced ap-
optotic nuclei when compared with the control cells (data not
shown), a result which might be due to the requirement of
ICAD to achieve functional cellular levels of the CAD short
forms.4. Discussion
We have described and characterized three novel splice
variants of the CAD gene. In spite of their low level of ex-
pression, there are several evidences that support that these
messengers are alternative variants rather than aberrant tran-
Fig. 5. Inhibition of apoptosis by ICAD is partially reverted by ex-
pressing isoforms of truncated CAD. (A) 293T cells were co-trans-
fected with 2 lg of the indicated expression plasmids that contain
N-terminally Flag-tagged ICAD and the diﬀerent alternative forms of
N-terminally HA-tagged CAD, together with 1 lg of a pEGFP-
expressing reporter construct. The data (meanS.E.M.) represent the
percentage of apoptotic nuclei, as revealed by the Hoechst staining, in
the population of eGFP positive cells. Experiment was repeated three
times. Asterisk indicates that the values are signiﬁcantly diﬀerent
ðP < 0:01Þ between the cultures transfected with ICAD alone and
those co-transfected with ICAD and the CAD short isoforms.
(B) Western blots of the corresponding transfected cell cultures were
analyzed with anti-FLAG M2 antibody or anti-HA antibody. Num-
bers in the middle panel indicate the position of full length HA-tagged
CAD (around 40 kDa) or the HA-tagged CAD fragments (around 12
kDa). An anti-eGFP antibody was used to control the comparable
eﬃciencies in transfection or expression that were obtained in the
diﬀerent experimental conditions. (C) Representative photographs: a
and b, cells transfected with the empty vector; c, cells transfected with
ICAD; and d, cells transfected with ICAD and CADþ7. In a, cells were
untreated, whereas in b, c and d cells were treated with 1 lM STP for
20 h. Scale bars, 20 lM.
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lymphocytes from ten unrelated individuals and are widely
expressed in a number of human tissues. Second, after exten-sive sequencing of several independent clones, no mutations in
the splicing consensus sequences neither in exon 2 nor exon 3
have been detected. Third, it is worth noting that the cryptic
splice donor and acceptor sites described for these splice
variants are in fact more consistent than the normally used
ones according to the consensus sequence [40]. And fourth,
western blot analysis of mouse tissue extracts showed an ex-
pression proﬁle for the diﬀerent truncated isoforms which is in
agreement with the RT-PCR data.
The ICAD/CAD system is mainly responsible for the in-
ternucleosomal DNA degradation and might be tightly regu-
lated to prevent the release of a potentially harmful
endonuclease in normal cells. Thus, ICAD binds to the nascent
protein of CAD through their N-terminal domains to ensure
the correct folding of a DNase which otherwise will result in a
non-functional conformation, and at the same time ICAD
remains complexed with CAD and inhibits CAD nuclease
activity [22]. The truncated products of CAD described here
lack the catalytic domain but retain the CIDE-N domain, a
motive implicated in homophilic protein–protein interactions
such as that between CAD and ICAD [23]. We demonstrated
that these truncated CIDE-N containing molecules are soluble
proteins which can interact with ICAD. Therefore, one pos-
sibility would be that these short forms could bind to ICAD to
act as negative regulators by interfering in the correct folding
of CAD. During the course of this work several abnormal
CAD transcripts have been described in human hepatoma cells
[16]. Although none of them match exactly with the ones de-
scribed here, some transcripts speciﬁc of, and abundant in,
poorly diﬀerentiated tumour cells codify for the CIDE-N do-
main of CAD. The authors speculate that these products may
interfere with the normal CAD activity and in turn may award
cells with survival advantages and carcinogenesis potential
[16]. Conversely, the cell death assays conducted in the present
study indicate that these short forms of CAD should in-
duce apoptosis rather than interfering with the proper CAD
activation.
It has been demonstrated that ICAD/CAD interaction is
mediated by binding of three functional domains of ICAD
(D1, D2 and D3) to two domains of CAD (CIDE and endo-
nuclease), where D1 interact with the CIDE domain of CAD
while D2 and D3 interacts with the catalytic domain of CAD
[26]. Full-length ICAD or either D1–D2 or D2–D3 double
domain fragments bind to CAD with higher aﬃnity and are
much more eﬀective inhibitors than the isolated domains
[25,26].
In STP-treated cultures, ICAD is degraded by active cas-
pase-3 and dissociated from CAD. The endonuclease can still
remain inhibited by the ICAD D1 domain, which interacts
with the regulatory domain of CAD thus preventing its proper
activation. It has been proposed that the residues of the EDG
loop of the CAD CIDE-N domain are important for the nu-
clease activity, possibly by interacting directly with the CAD
catalytic domain [23,24]. The fragments described here could
displace the interaction between the ICAD D1 domain and
CAD, allowing the regulatory domain of CAD available for
the interaction with the catalytic domain. Moreover, the CAD
isoforms described here contain the EDG loop and could act
directly as trans-activators of the endonuclease activity. What
could be the relevance of these products in a normal cell re-
mains to be explained. In the model of endonuclease activation
described above, either an excess of ICAD or a defect in CIDE
240 J.R. Bayascas et al. / FEBS Letters 566 (2004) 234–240proteins could prevent proper activation of CAD once released
from the DFF complex. The CAD isoforms described here are
the ﬁrst evidence of a CIDE-N only molecule produced
physiologically. We favour the hypothesis that truncated forms
of CAD could serve to modulate the endonuclease activity
after apoptotic induction.
In conclusion, in this study we have identiﬁed three novel
splice variants of the CAD gene in which the open reading
frame is truncated after the second exon. These CIDE-N
containing proteins are produced in physiological conditions
and, unlike full-length CAD, these truncated forms are soluble
proteins which can interact with ICAD and modulate the ac-
tivity of the DFF complex. Altogether, our results suggest that
CAD short isoforms can induce apoptosis in a caspase-
dependent manner. Their function could be relevant during the
apoptotic process of cellular systems in which high amounts of
ICAD or absence of CIDE proteins could obstruct the proper
activation of the endonuclease activity during apoptosis.
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